BNET Industries
Market Cap:$249.5K
Last Fiscal Year Sales:$17.6K
- Public
- US
Dow Jones Description
Nanobac Pharmaceuticals, Incorporated and its subsidiaries (which may be referred to as "Nanobac", "the Company", "NNBP", "we", "us", or "our") is a research-based bio-lifescience company formed in 1994 as a Florida corporation. The current business described below commenced in June 2003 with the acquisition of NanobacLabs Pharmaceuticals, Inc. We are a life science company dedicated to the discovery and developments of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles ("CNPs"), otherwise known as "nanobacteria". The Company's research is directed toward establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease. Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products (blood and tissue tests) include assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. Calcification is a significant feature in most diseases that are leading causes of death, including heart disease. ...
Chief
E Olavi KajanderContact Information
2727 W Martin Luther King Blvd Ste 850
Tampa, Florida 33607
8132581064X224
Peer Companies
NAICS Code Medical Laboratories: 621511
News & Analysis
Filter by
nanobac pharmaceuticals inc. - All News and Analysis
Speak with other shareholders about: (PINKSHEETS: PNHL), (NASDAQ: ACTU), (Pink Sheets: WNBD), (OTCBB: DNAG).
M2 PRESSWIRE-5 February 2008-Stockwire.com: Speak with other shareholders about: (PINKSHEETS: PNHL), (NASDAQ: ACTU), (Pink Sheets: WNBD), (OTCBB: DNAG).C1994-2008 M2 COMMUNICATIONS LTD RDATE:05022008 AUSTIN, TX -- Are you looking to speak with other investors about your favorite stock in real-time?...
Nanobac Pharmaceuticals Inc. Launches Landmark Study to Explore Heart Disease Properties of Calcifying Nanoparticles
TAMPA, Fla. -- Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News; "Nanobac" or "the Company") and Mayo Clinic have reached an agreement to study whether calcifying nanoparticles, already found in atherosclerotic plaque, are infectious and contribute to the onset of heart disease. The identification of the cause of calcification would be...
Issues Updates on Nanobac Pharmaceuticals Inc.
M2 PRESSWIRE-25 September 2006-www.MarketGainer.com: Issues Updates on Nanobac Pharmaceuticals IncC1994-2006 M2 COMMUNICATIONS LTD RDATE:25092006 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Today's activity on the...
BBSE, CHYS, MPAQ, NNBP Have Also Been Added To Naked Short List Today.
M2 PRESSWIRE-18 April 2006-BUYINS.NET: BBSE, CHYS, MPAQ, NNBP Have Also Been Added To Naked Short List TodayC1994-2006 M2 COMMUNICATIONS LTD RDATE:18042006 www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list:...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| E Olavi Kajander | Chief |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Alex H Edwards | Member of the Board of Directors and Assists |
| Stephan Rechtschaffen | Board of Directors |
Dr. E. Olavi Kajander is Chief Research and Science Officer at Nanobac Pharmaceuticals in Tampa. He founded Nanobac OY, a Finnish research and development company located in Kuopio, Finland which is is now a subsidiary of Nanobac Pharmaceuticals. Dr. Kajander also founded Abcell Corporation, a medical diagnostics company. Dr. Kajander is a professor at the University of Kuopio. His position at the University of Kuopio has elevated over the time of his tenure from Ph.D. candidate, to doctorate, assistant professor, associate professor and now as docent. He has taught many courses at the university for more than 12 years and was the Research Director in the Department of Biochemistry. Dr. Kajander was a Scripps Clinic & Resident Foundation post-doctoral research fellow in La Jolla, California. He has authored or co-authored more than 70 scientific research papers and review articles, two letters and more than 50 scientific abstract publications as well as several invited editorials in scientific texts and journals. He also co-authored a Microbiology textbook chapter on Nanobacteria. He has been involved in the production of a number of videos and documentaries about his discovery of Nanobacteria. He pioneered families of U.S. patents effective in many countries and now assigned to Nanobac Pharmaceuticals.
| Organization | Position | Status |
|---|---|---|
| Nanobac Life Sciences, Inc. | Chief Research and Science Officer | Current |
| Nanobac Pharmaceuticals, Inc. | Chief | Current |
| Abcell | Founder | Former |
Alex Edwards is a member of the Board of Directors and assists the company in a consultative capacity. From May 2002 through present, Mr. Edwards has been a Managing Director of 360 Partners, as well as President & CEO of 360 Energy. From January 1997 to May 2002, he was an executive with SRI/Surgical Express. His roles ranged from Vice President/General Manager to President. From February 1993 through December 1997, he worked in Sales and Marketing with Dianon Systems, Inc. His positions included Sales and Sales Management roles as well as Field and Corporate Marketing. Mr. Edwards served as an Officer in the United States Navy with duty assignments ranging from Shipboard Divisional Leadership to Executive Assistant for the Naval Surface Group Commander in Norfolk, Virginia. Mr. Edwards is a 1987 graduate of the United States Naval Academy.
| Organization | Position | Status |
|---|---|---|
| Nanobac Life Sciences, Inc. | President & CEO | Current |
| Nanobac Life Sciences, Inc. | Board of Directors | Current |
| Nanobac Pharmaceuticals, Inc. | Member of the Board of Directors and Assists | Current |
| Nano Chemical Systems Holdings, Inc. | Chief Executive Officer | Former |
| Sports.Com | CEO | Former |
| Energy Limited | CEO | Former |
| Sports.Com | President | Former |
| Energy Limited | President | Former |
| Nano Chemical Systems Holdings, Inc. | Chief Financial Officer | Former |
| SRI/Surgical Express, Inc. | Executive | Former |
| Dianon Systems, Inc. | Former |
| Organization | Position | Status |
|---|---|---|
| Vitality Corporation | Co-Author | Current |
| Wellness Inc. | Co-Author | Current |
| Nanobac Life Sciences, Inc. | Current | |
| Nanobac Pharmaceuticals, Inc. | Board of Directors | Current |
| Omega Institute | Co-Founder | Former |
| Rhinebeck Health Center | Developer | Former |
| Rhinebeck Health Center | Director | Former |
Industry Transcripts by Seeking Alpha
-
Medtronic Inc. F2Q10 (Qtr End 10/30/09) Earnings Call Transcript
on Nov 24, 2009about MDT
-
ZOLL Medical Corporation F4Q09 (Qtr End 27/09/09) Earnings Call Transcript
on Nov 11, 2009about ZOLL
-
RadNet, Inc. Q3 2009 Earnings Call Transcript
on Nov 09, 2009about RDNT
-
Cytori Therapeutics Q3 2009 Earnings Call Transcript
on Nov 09, 2009about CYTX
-
StoneMor Partners L.P. 3Q09 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 09, 2009about STON
IndustryTop Rated
- Why So Many Insured People Have Big Medical Debts 5 votes
- Physicians Know We Need Reform 4 votes
- Healthcare Roundup: Medical Office Space in Demand, Blues Companies See Lower Income, Two Sides of Health Insurance, and More 3 votes
- Hospital Chain's Turnaround Raises Health Spending 3 votes
- Healthcare Is Still Adding Jobs, Despite Recession 3 votes



